| 464.93 -7.06 (-1.5%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 581.22  |
1-year : | 607.34 |
| Resists | First : | 497.62 |
Second : | 519.98 |
| Pivot price | 488.81 |
|||
| Supports | First : | 461.45 |
Second : | 383.92 |
| MAs | MA(5) : | 474.38 |
MA(20) : | 494.76 |
| MA(100) : | 449.73  |
MA(250) : | 367.11 |
|
| MACD | MACD : | -3.9 |
Signal : | 1 |
| %K %D | K(14,3) : | 8.9 |
D(3) : | 9.6 |
| RSI | RSI(14): 35.5 |
|||
| 52-week | High : | 519.98 | Low : | 266.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ UTHR ] has closed above bottom band by 1.9%. Bollinger Bands are 15.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 473.15 - 477.69 | 477.69 - 480.44 |
| Low: | 451.7 - 457.7 | 457.7 - 461.33 |
| Close: | 458.08 - 467.81 | 467.81 - 473.68 |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Mon, 19 Jan 2026
United Therapeutics Corporation (UTHR): A Bull Case Theory - Yahoo Finance
Sun, 18 Jan 2026
The Bull Case For United Therapeutics (UTHR) Could Change Following Phase 3 Ralinepag Trial Completion - Learn Why - simplywall.st
Fri, 16 Jan 2026
Assessing United Therapeutics (UTHR) Valuation After Recent Share Price Pullback - simplywall.st
Fri, 16 Jan 2026
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term - Yahoo Finance
Fri, 16 Jan 2026
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term - Nasdaq
Thu, 15 Jan 2026
Assessing United Therapeutics (UTHR) After Strong Multi‑Year Gains And Recent Share Price Weakness - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 99.1 (%) |
| Shares Short | 2,100 (K) |
| Shares Short P.Month | 1,650 (K) |
| EPS | 26.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 153.61 |
| Profit Margin | 40.6 % |
| Operating Margin | 48.6 % |
| Return on Assets (ttm) | 13.1 % |
| Return on Equity (ttm) | 20 % |
| Qtrly Rev. Growth | 6.8 % |
| Gross Profit (p.s.) | 64.32 |
| Sales Per Share | 72.68 |
| EBITDA (p.s.) | 37.15 |
| Qtrly Earnings Growth | 12.1 % |
| Operating Cash Flow | 1,560 (M) |
| Levered Free Cash Flow | 735 (M) |
| PE Ratio | 17.62 |
| PEG Ratio | 0 |
| Price to Book value | 3.02 |
| Price to Sales | 6.39 |
| Price to Cash Flow | 12.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|